Agilent's Q2 Revenue Dips to $1.57B Amid Market Headwinds
Ticker: A · Form: 10-Q · Filed: Jun 2, 2025 · CIK: 1090872
| Field | Detail |
|---|---|
| Company | Agilent Technologies, Inc. (A) |
| Form Type | 10-Q |
| Filed Date | Jun 2, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: Life Sciences, Diagnostics, Analytical Instruments, Q2 Earnings, Revenue Decline, Net Income Drop, Market Headwinds
TL;DR
Agilent's Q2 results are a red flag; revenue and net income drops suggest a tough market, so tread carefully.
AI Summary
Agilent Technologies, Inc. reported a revenue of $1.57 billion for the three months ended April 30, 2025, a decrease from $1.69 billion in the prior-year period. Net income for the quarter was $287 million, down from $330 million in the same period last year. For the six months ended April 30, 2025, revenue was $3.14 billion, a decline from $3.38 billion in the comparable period of 2024. Net income for the six-month period decreased to $570 million from $670 million. Product revenue for the three months ended April 30, 2025, was $909 million, a decrease from $1.01 billion, while service revenue was $661 million, up from $679 million. The company's strategic outlook remains focused on innovation in life sciences, diagnostics, and applied markets, despite facing headwinds reflected in the revenue and net income declines. Risks include ongoing market demand fluctuations and competitive pressures in the analytical instrument sector.
Why It Matters
Agilent's Q2 performance, with a revenue decline to $1.57 billion and net income falling to $287 million, signals a challenging environment for investors in the life sciences and diagnostics sector. This downturn could impact employee morale and future hiring plans, while customers might see increased competition among suppliers leading to potential pricing benefits or, conversely, reduced R&D investment from Agilent. The broader market for laboratory analytical instruments, where Agilent is a key player, may experience a ripple effect, indicating a potential slowdown in capital expenditures within research and industrial applications. Competitors like Thermo Fisher Scientific and Danaher will be closely watching these results for shifts in market share and demand.
Risk Assessment
Risk Level: medium — The risk level is medium due to the consistent decline in both revenue and net income across the three-month and six-month periods ended April 30, 2025. Revenue for the quarter decreased from $1.69 billion to $1.57 billion, and net income fell from $330 million to $287 million, indicating a weakening financial performance. This sustained downward trend, including a six-month revenue drop from $3.38 billion to $3.14 billion, suggests ongoing operational challenges.
Analyst Insight
Investors should consider holding off on new investments in Agilent until there's clear evidence of a turnaround in revenue and net income trends. Current shareholders should monitor upcoming earnings calls for management's strategy to address the declining sales and profitability, and evaluate if the long-term growth prospects still align with their investment thesis.
Financial Highlights
- revenue
- $1.57B
- net Income
- $287M
- revenue Growth
- -7.1%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $909M | -10.0% |
| Service Revenue | $661M | -2.7% |
Key Numbers
- $1.57B — Q2 2025 Revenue (Decreased from $1.69 billion in Q2 2024, indicating a 7.1% decline.)
- $287M — Q2 2025 Net Income (Down from $330 million in Q2 2024, representing a 13% decrease.)
- $3.14B — Six-Month 2025 Revenue (Decreased from $3.38 billion in the prior six-month period, a 7.1% drop.)
- $570M — Six-Month 2025 Net Income (Fell from $670 million in the prior six-month period, a 14.9% decline.)
- $909M — Q2 2025 Product Revenue (Decreased from $1.01 billion in Q2 2024, showing a 10% decline in product sales.)
- $661M — Q2 2025 Service Revenue (Increased from $679 million in Q2 2024, showing a slight increase in service sales.)
Key Players & Entities
- AGILENT TECHNOLOGIES, INC. (company) — filer of the 10-Q
- Bloomberg (company) — publisher of the analysis
- SEC (regulator) — regulator for 10-Q filings
- Thermo Fisher Scientific (company) — competitor in the analytical instrument sector
- Danaher (company) — competitor in the analytical instrument sector
- $1.57 billion (dollar_amount) — Agilent's revenue for Q2 2025
- $287 million (dollar_amount) — Agilent's net income for Q2 2025
- $3.14 billion (dollar_amount) — Agilent's revenue for the six months ended April 30, 2025
- $570 million (dollar_amount) — Agilent's net income for the six months ended April 30, 2025
- $909 million (dollar_amount) — Agilent's product revenue for Q2 2025
FAQ
What were Agilent Technologies' total revenues for the three months ended April 30, 2025?
Agilent Technologies reported total revenues of $1.57 billion for the three months ended April 30, 2025, a decrease from $1.69 billion in the same period of the prior year.
How did Agilent's net income change for the quarter ended April 30, 2025?
For the quarter ended April 30, 2025, Agilent's net income was $287 million, which is a decrease from $330 million reported in the comparable quarter of the previous year.
What was the trend in Agilent's revenue for the six months ended April 30, 2025?
Agilent's revenue for the six months ended April 30, 2025, was $3.14 billion, a decline from $3.38 billion in the corresponding six-month period of 2024.
Did Agilent's product revenue increase or decrease in Q2 2025?
Agilent's product revenue decreased in Q2 2025, falling to $909 million from $1.01 billion in the three months ended April 30, 2024.
What is Agilent's fiscal year end date?
Agilent Technologies' fiscal year ends on October 31, as stated in the filing data.
What are the primary business segments of Agilent Technologies?
Agilent Technologies operates in the life sciences, diagnostics, and applied markets, providing laboratory analytical instruments and services.
What are the key risks highlighted by Agilent's recent financial performance?
The key risks highlighted by Agilent's recent financial performance include ongoing market demand fluctuations and competitive pressures, evidenced by the consistent decline in both revenue and net income across reported periods.
How does Agilent's Q2 2025 performance compare to its Q2 2024 performance?
Agilent's Q2 2025 revenue of $1.57 billion was lower than Q2 2024's $1.69 billion, and net income of $287 million was down from $330 million in Q2 2024.
What was Agilent's service revenue for the three months ended April 30, 2025?
Agilent's service revenue for the three months ended April 30, 2025, was $661 million, which was an increase from $679 million in the prior-year period.
What is the significance of the decline in Agilent's net income for investors?
The decline in Agilent's net income to $287 million for the quarter and $570 million for the six months signals reduced profitability, which could impact shareholder returns and future investment in growth initiatives, making the stock less attractive to investors seeking strong earnings growth.
Risk Factors
- Fluctuating Market Demand [high — market]: The company faces risks from ongoing fluctuations in market demand for its products and services. This is evidenced by the 7.1% year-over-year revenue decline in the first six months of fiscal year 2025, indicating a softening in customer spending.
- Competitive Pressures [medium — market]: Agilent operates in a highly competitive landscape within the analytical instrument sector. Intense competition can impact pricing power and market share, potentially affecting revenue and profitability.
- Supply Chain Disruptions [medium — operational]: While not explicitly detailed in the summary, global supply chain challenges can impact the company's ability to manufacture and deliver products, leading to potential delays and increased costs.
- Compliance with Regulations [medium — regulatory]: As a global company operating in life sciences and diagnostics, Agilent must comply with various complex and evolving regulatory requirements in different jurisdictions, which can lead to increased compliance costs and potential penalties.
Industry Context
Agilent Technologies operates in the life sciences, diagnostics, and applied markets, a sector characterized by innovation and significant R&D investment. The industry is competitive, with players like Thermo Fisher Scientific, Danaher, and Merck KGaA vying for market share. Trends include increasing demand for personalized medicine, advanced diagnostics, and sophisticated analytical tools for research and quality control.
Regulatory Implications
The company's operations in diagnostics and life sciences are subject to stringent regulatory oversight from bodies like the FDA and EMA. Compliance with evolving regulations for medical devices and laboratory practices is critical and can impact product development timelines and market access.
What Investors Should Do
- Monitor competitive landscape and market share shifts.
- Analyze the drivers of product revenue decline.
- Assess the sustainability of service revenue.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the source of the financial data and analysis presented.)
- Fiscal Year End
- The last day of a company's accounting year, which may not coincide with the calendar year end. (Agilent's fiscal year ends on October 31st, meaning the reported quarter (ended April 30, 2025) is Q2 of their fiscal year 2025.)
- Product Revenue
- Revenue generated from the sale of physical goods, such as analytical instruments and consumables. (A key segment of Agilent's business, showing a decline in the current quarter.)
- Service Revenue
- Revenue generated from services, such as maintenance, support, and consulting related to the company's products. (Another significant segment, which showed a slight decrease in the current quarter.)
Year-Over-Year Comparison
Compared to the prior-year period, Agilent Technologies reported a 7.1% decrease in revenue for both the three and six-month periods ending April 30, 2025. Net income also saw a significant decline, down 13% for the quarter and 14.9% for the six months. Product revenue experienced a notable 10% drop, while service revenue saw a slight decrease. No new significant risks were highlighted in the provided summary, but the existing risks of market demand and competition appear to be materializing.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on June 2, 2025 regarding AGILENT TECHNOLOGIES, INC. (A).